Search results
Results from the WOW.Com Content Network
PeptiDream Announces License of PeptiDream's Peptide Discovery Platform System (PDPS) Technology to Bristol-Myers Squibb and Extension of the Macrocyclic Peptide Drug Discovery Alliance Between ...
Ipglycermides are non-natural macrocyclic peptide (MCP) inhibitors of cofactor independent phosphoglycerate mutases (iPGM) discovered by the research laboratories of Dr. James Inglese of the National Institutes of Health and Prof. Hiroaki Suga of the University of Tokyo.
Macrocyclic peptides are the “Goldilocks” chemical modality because their intermediate size combines the favorable properties of both small molecules and biologics. “I am thrilled to join UNP’s team of innovators in macrocyclic peptide drug discovery at such an exciting stage of the company,” said Bailey.
“RFpeptides is a novel deep learning pipeline that enables the precise design of macrocyclic peptide binders for a wide range of therapeutic protein targets,” said Gaurav Bhardwaj, Ph.D., Assistant Professor, Department of Medicinal Chemistry at UW School of Pharmacy and Institute for Protein Design at the University of Washington, and Co ...
Enlicitide chloride (INN; [1] previously known as MK-0616) is a macrocyclic peptide investigational drug who is being evaluated for the treatment of hypercholesterolaemia. It is a PCSK9 inhibitor. [2] Merck has launched a Phase 3 clinical trial to evaluate the efficacy and safety of MK-0616 in Adults With Hypercholesterolemia. [3] [4]
Peptide therapeutics are peptides or polypeptides (oligomers or short polymers of amino acids) which are used to for the treatment of diseases.Naturally occurring peptides may serve as hormones, growth factors, neurotransmitters, ion channel ligands, and anti-infectives; peptide therapeutics mimic such functions.
This pharmacology -related article is a stub. You can help Wikipedia by expanding it.
Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. [2] The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances [3], which improves drug characteristics like retention and solubility. [4]